UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended July 31, 1996
Commission File Number 2-96510-NY

DRUG GUILD DISTRIBUTORS, INC.
(Exact name of Registrant as specified in its charter)

New Jersey 11-2269958
(State or other jurisdiction of (I.R.S. Employer I.D. No.)
incorporation or organization)

350 Meadowland Parkway, Secaucus, New Jersey 07096
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (201) 348-3700

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

YES |X| NO |_|

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
registrant's best knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendments to
this Form 10-K. |X|

There is no trading market for either class of the Registrant's voting
securities.

As of July 31, 1996 there were outstanding 10,022,667 shares of the Registrant's
Common Stock and 25,893.44 shares of the Registrant's Preferred Stock.

Documents incorporated by reference: None

Page 1 of ___ pages
The Exhibit Index is located at Page __

PART I

Item 1. Business.

Drug Guild Distributors, Inc., referred to herein as the "Company" or the
"Registrant," is engaged in the business of distributing at wholesale a wide
variety of products almost exclusively to drugstores and health and beauty aid
stores primarily in the State of New Jersey and the Greater New York City
metropolitan area. Approximately 1% of sales are to nursing homes and less than
1/4 of 1% of sales are to employees of the Company. The products distributed can
be separated into four groups: (1) legend drugs, which are dispensed to the
public only on a doctor's prescription and take the form of pills, tablets and
capsules, the ingredients of which are sometimes sold in bulk by the Company;
(2) patent or non-legend drugs, which do not require a prescription and include
such items as cough medicines and aspirin; (3) sundries, which include such
items as clocks, soaps, deodorants, hairdryers and most other non-pharmaceutical
products commonly sold in drugstores; and (4) certain items sold under the
Company's private labels, including vitamins, shampoos and cough syrups. The
percentage of sales of the four product groups are approximately as follows:
legend drugs: 80%; non-legend drugs: 13%; sundries: 5%; and private labels: 2%.

The preponderance of the Company's inventory purchases are made directly
from the manufacturers and no single supplier accounts for more than 5% of the
Company's dollar amount of purchases. In the opinion of management, there are
alternative sources of supply for virtually all the products sold by the Company
and the loss of any particular supplier would not have a materially adverse
effect on the Company. The Company has written agreements with several of its
largest suppliers, but these agreements do not require any prescribed level of
purchases by the Company nor do they require the supplier to sell any given
amount to the Company or guarantee any prices.

In May 1996, as a result of a physical inventory, the Company discovered a
defalcation of approximately $7,400,000. The Company believes that entries in
its perpetual inventory and units sold were improper. The Company extrapolated
the effects of these entries based on unit costs, units sold and sales dollars.
The Company believes that similar inventory defalcations also occurred during
prior years and amounted to $5,200,000 and $2,100,000 for the years ended July
31, 1995 and 1994, respectively. Those amounts are included in the cost of sales
for those years. The Company's reported inventory values on its fiscal 1995 and
1994 balance sheets were based on results of physical counts and, accordingly,
the Company believes that its reported financial condition and net income (loss)
for all periods is fairly presented.

The Company believes it may have insurance coverage totaling $2,000,000 as
a possible recovery against the inventory defalcation. The Company has not
provided for any recovery in its financial statements for the period ended July
31, 1996, since at this time, such recovery cannot be assured.

The Company has engaged a private contractor to investigate the
defalcation and is cooperating with federal, state and local law enforcement
authorities to determine the source of the

defalcation. The Company has also made changes in personnel and security
procedures which it believes will eliminate defalcations in the future. The
Company, upon reconciling its physical inventory for the fiscal year ended July
31, 1996, believes that no defalcations occurred from the time of discovery in
May 1996 through July 31, 1996.

The Company sells to approximately 800 customers, most of which are
drugstores located in New Jersey and the Greater New York City metropolitan
area. The Company has no control over the pricing policies of its customers and
it believes that its customers sell over a wide range of prices. There is no
requirement that a customer purchase any given portion of its inventory from the
Company, but the Company believes that it supplies from 25% to 50% of an average
customer's inventory. One customer accounted for 5.8% of the Company's sales. No
other customer accounts for more than 5% of the Company's total sales.

A substantial percentage of the Company's customers are shareholders of
the Company. Approximately 40% of the issued and outstanding Common Stock of the
Company is owned by its customers. (An additional 50% of the issued and
outstanding Common Stock of the Company is owned by affiliates of the customers
and other persons related to the affiliates.) Such "Shareholder-customers"
account for more of the Company's sales per store, on the whole, than non
Shareholder-customers. All Shareholder-customers of such stock have pledged
their shares to the Company to secure payment of amounts owed the Company for
purchases. It is the policy of the Company, with respect to a customer which has
pledged a predetermined number of shares of the Company's Common Stock or other
collateral acceptable to the Company to secure its accounts, to grant to such
customer, provided that such customer maintains its account in accordance with
certain standards, credit terms which are superior to credit terms given to
customers who do not pledge shares as security. The Company responds to defaults
in payments upon goods purchased by customers on an ad hoc basis. Upon such a
default by a Shareholder-customer, it is the policy of the Company to continue
shipping goods and to forego instituting legal actions for a longer period of
time than with respect to defaults by customers who do not pledge shares. Except
for superior credit terms, Shareholder-customers receive the same terms with
respect to sales of goods as non Shareholder-customers. The foregoing policy is
subject to modification or discontinuance at any time at the election of the
Company.

If a Shareholder-customer defaults in the payment of amounts owed the
Company for merchandise, the Company may elect to terminate the customer's
interest in the shares and credit the customer's account with an amount equal to
the lesser of (a) the FIFO Book Value, or (b) the greater of cost or par value
of the shares. In the case of a shareholder owning shares which were both
purchased by the shareholder and shares received by such shareholder as a
dividend, such categories of stock will be considered separately in determining
"the greater of cost or par value."

The Company employs sales representatives, but the majority of customers'
orders are taken by telephone or through computer terminals at the Company's New

Jersey office. Sales promotions of particular items are initiated on a regular
basis. In connection with such promotions, the Company supplies its customers
with window signs and appropriate flyers for consumers. Many

of the Company's customers, and particularly Shareholder-customers, identify
themselves as "Drug Guild" stores.

Merger with Neuman Distributors, Inc. On September 24, 1996, the Company's
Board of Directors approved an agreement for the Company to be merged with
Neuman Distributors, Inc., a wholly owned subsidiary of Neuman Health Services,
Inc., both New Jersey corporations. On October 25, 1996, a definitive merger
agreement was executed by the Company and Neuman to effectuate the merger
whereby, if all conditions precedent of the agreement are satisfied, the
Company's stockholders would receive 23% of the common stock of Neuman Health
Services, Inc. However, the proposed merger is subject to the approval by the
Company's shareholders having beneficial ownership of a majority of the issued
and outstanding shares of each of the Company's common and preferred stock.

Neuman is the largest privately-held and the nation's seventh largest
wholesale distributor of pharmaceutical and related health and beauty care
products. Its customers include independent and chain drug stores, hospitals,
alternate care centers and the pharmacy departments of supermarkets and mass
merchandisers located throughout the northeastern United States.

As a full-service wholesale distributor, Neuman complements its
distribution activities by offering a broad range of value-added support
services to assist Neuman's customers and suppliers in maintaining and improving
their market positions and to strengthen Neuman's role in the channel of
distribution. These support services include computerized order entry, and order
confirmation systems, customized invoicing, generic sourcing programs, product
movement and management reports, consultation on store operation and
merchandising, and customer training. Most customers transmit merchandise orders
directly to Neuman's data processing system through computerized order entry
devices. Neuman's proprietary software systems feature unique systems specially
designed to help its customers order more efficiently, contain costs and monitor
their purchases which are covered by group contract purchasing arrangements.

In addition to its core wholesaling activities, Neuman operates a separate
wholesale durable medical equipment subsidiary, Home Health Care of New Jersey,
which offers Neuman's customers a full line of home health care products and
provides Neuman additional opportunity for growth and profitability. Further,
Neuman has an investment in a joint venture with KVM Technologies, a Houston,
Texas based company primarily developing the ENVOY automated medication delivery
system for hospitals, nursing homes and large pharmaceutical dispensing
operations; and MediView, a Glen Rock, New Jersey based company primarily
developing the MediView kiosk for retail marketing, couponing and sales
enhancement at the retail store level. These investments and joint ventures are
part of Neuman's overall strategy of developing diversified products and
services to enhance the profitability of its business and that of its customers
and suppliers.

In January 1994, Neuman acquired OCP America/Ketchum ("OCP"), a South
Plainfield, New Jersey based drug wholesaler. As a result of the acquisition,
Neuman now maintains a network of distribution centers enabling it to routinely
service a geographic area in which approximately 40% of the continental United
States population resides.

Neuman completed two acquisitions in the four years prior to the OCP
acquisition. Neuman acquired James Wholesale Drug Company, a Rahway, New Jersey
based drug wholesaler serving customers located primarily in the state of New
Jersey. In January 1993, Neuman acquired H.K. Hineline Company, a Utica, New
York based drug wholesaler servicing customers located primarily in northern and
central New York state. On May 10, 1996, Neuman completed the acquisition of the
assets of Advantage buying cooperative, a purchasing group consisting of
approximately 1,000 members in the states of New Jersey, Pennsylvania and New
York.

Employees. The Company employs approximately 312 persons on a full time
basis. Approximately 217 are warehouse personnel, 66 are clerical and 29 are
executives, salespersons and administration. The warehouse and clerical
personnel are covered by a collective bargaining agreement with Local 815,
International Brotherhood of Teamsters, which expires on February 15, 1998.
There has never been a strike or labor stoppage and the Company believes that
its relationship with its employees is excellent.

Competition. Competition in the wholesale drug and drugstore supply
business is intense and the Company competes in its marketing region with a
large number of suppliers.

Financial Consultant On July 6, 1993, the Company entered into an
agreement with Joseph B. Churchman, whose address is P.O. Box 648, Rehoboth
Beach, Delaware 19971. The Company has engaged Mr. Churchman's services as a
pharmaceutical industry and financial consultant to the Company. The agreement
may be terminated by either party upon proper notice. Mr. Churchman is paid
$1,500.00 per day for services rendered to the Company. His per diem fee is to
be deducted from a success fee or finders fee payable to Mr. Churchman in the
amount of one-half of one percent (.5%) of the total consideration of a Company
"transaction" which results from his efforts. The word transaction as used
herein means, in the broadest sense, the acquisition, consolidation, merger,
sale, purchase or other union of the Company with another entity.

On June 18, 1996, the Company's Board of Directors appointed Mr. Churchman
as the Chairman of the Company's Management Committee which allows for all
operational decisions to be passed upon by Mr. Churchman. It was agreed by the
Board of Directors that Mr. Churchman would (i) receive an indemnification
agreement; (ii) be added to the Company's existing director and officer
liability insurance; and (iii) be compensated at the rate of $200/hour for his
services plus out of pocket expenses. This appointment replaces the Company's
existing financial consulting arrangement with Mr. Churchman.

Amendment to By-Laws. On October 12, 1993, the Company amended its By-laws
to provide that the Executive Committee shall have and exercise all the
authority of the Board of Directors in lieu of the Board of Directors to the
extent permitted by New Jersey Statute Annotated 14A:6-9, See Exhibit 3(d).

Item 2. Properties.

The Company occupies a modern cinderblock and steel office and warehouse
facility in Secaucus, New Jersey. The facility, which was built to the Company's
specifications, contains approximately 155,000 square feet and houses all the
Company's office and much of its warehouse functions. The Company leases the
building from an unaffiliated entity under a lease which expires on May 31,
2005. For the fiscal years 1996-2005, the annual base rental will be an average
of $785,758.

The Company leases another warehouse facility in Secaucus, New Jersey. The
building, which was modified to accommodate the Company, contains 33,280 square
feet and houses additional warehouse space. The Company leases the building from
an unaffiliated entity under a lease which expires on May 31, 2005. For the
fiscal years 1996-2000, the annual base rental will be $158,080 and for the
fiscal years 2000-2005, the annual base rental will be $183,040.

The leases are net leases requiring the Company to pay, in addition to the
base rental, substantially all real estate taxes, repairs and other charges
incident to the ownership of the properties. The real estate taxes paid by the
Company on account of the fiscal year ended July 31, 1996, were approximately
$180,000.

In addition to the foregoing, the Company subleases an additional
warehouse facility in Secaucus, New Jersey from an unrelated third-party. The
facility contains approximately 36,977 square feet. The term of the lease, which
expired on June 30, 1995, has been extended to March 31, 1997. The annual rent
for the premises is $175,640.76 or $4.75 per square foot, "gross". Rent includes
taxes, utilities, alarm system and other related charges.

The Company owns the preponderance of its office and warehouse equipment,
all of which is in excellent condition. The Company also owns 51 delivery
trucks, most of which are operated under a contractual arrangement by a
corporation unaffiliated with the Company or management.

Item 3. Legal Proceedings.

None

Item 4. Submission of Matters to a Vote of Security Holders.

None.

PART II

Item 5. Market for Registrant's Common Equity and Related Stockholder Matters.

There is no existing public market for any of the Company's securities.

As of July 31, 1996, there were approximately 398 holders of record of the
Company's Common Stock and approximately 39 holders of record of its Preferred
Stock. Since 19 Shareholders owned both Common and Preferred Stock, the Company
had 418 Shareholders as of that date.

The Company has never paid a cash dividend and management does not expect
to pay cash dividends in the future.

Item 6. Selected Financial Data Income Statement Data:

Years Ended July 31,
1996 1995 1994 1993 1992
---- ---- ---- ---- ----
000's omitted (A)
Income Statement Data
Net Sales 501,383 $493,827 $407,969 $387,252 $346,448
Net Income (Loss) (2,264) (505) 308 1,707 1,601
Net Income (Loss)
Attributable to
Common Stockholders (2,455) (796) (172) 1,316 1,184
Earnings (Loss) Per
Common Share (B) (0.24) (0.08) (0.01) 0.14 0.13(C)

Balance Sheet Data
Working Capital 7,856 11,381 13,920 13,566 11,630
Total Assets 105,974 113,266 103,669 97,209 93,220
Long-Term Liabilities 1,070 1,124 1,558 2,063 2,358
Preferred Stock 2,589 3,933 5,223 4,802 4,678
Stockholders' Equity 12,619 14,966 15,423 14,720 12,511
Stockholders' Equity
Per Common Share 1.26 1.49 1.56 1.56 1.37(C)
FIFO Book Value
Per Share (D) 1.55 2.10 2.27 2.27 2.03(C)
Ratio of Earnings
to Fixed Charges 0.31 0.89 1.16 1.91 1.87

- ----------
(A) Except Earnings (Loss) Per Common Share; Stockholder's Equity Per Common
Share; FIFO Book Value Per Share and Ratio of Earnings to Fixed Charges.

(B) See Exhibit 11 to Financial Statements.

(D) Calculated with inventory and tax liabilities based on the first-in,
first-out (FIFO) inventory method in connection with the Company's right
of first refusal and right of the holders of Preferred Stock to have their
stocks redeemed.

The table above is derived from the historical financial statements of the
Company set forth elsewhere herein as they relate to the balance sheets at July
31, 1996 and July 31, 1995 and to the statements of operations for the years
ended July 31, 1996, 1995 and 1994 and should be read in conjunction with such
financial statements, including the notes thereto.

Item 7. Management's Discussion and Analysis of Financial Condition and Results
of Operations

Financial Condition at July 31, 1996 Compared to Financial Condition
at July 31, 1995.

For the year ended July 31, 1996, the Company's Current Assets decreased to
$97,552,000 from $104,624,000 and its Current Liabilities decreased to
$89,966,000 from $93,242,000. The decreases were attributable to lower inventory
offset by higher receivables. The Company's ratio of Current Assets to Current
Liabilities remained the same at 1.1:1. The decrease in total Stockholders'
Equity to $12,619,000 from $14,967,000 was primarily attributable to the net
loss for the year.

The Company has an accounts receivable and inventory financing arrangement with
a bank (the "Agreement") under which it can borrow up to 70% of its eligible
accounts receivable and up to 50% of its eligible inventory, as defined in the
Agreement.

As of July 31, 1996, there were $56,100,000 of such eligible accounts receivable
out of a total of $64,000,000, or 88%, and $34,000,000 of eligible inventory
(calculated on FIFO Basis), an amount in excess of 99% of total inventory. Under
the Agreement, the maximum amount the Company can borrow on its inventory is
$30,000,000; and the maximum combined borrowing limit for accounts receivable
and inventory is $80,000,000. These limits are determined by the bank and may be
raised or lowered by the bank at its discretion.

Total borrowing upon the line of credit equaled $53,104,000 on July 31, 1996. On
such date the interest rate with respect to such financing was the prime
interest rate plus 1 1/4% (a total of 9 1/2%).

Inflation. The Company attempts to pass along price increases from its suppliers
as soon as it is notified of those increases so as to preserve its gross profit
margin and, subject to competitive pressures on particular products, is

generally successful in doing so. Accordingly, the historical effect of
inflation has been to increase the Company's revenues and profits.

Fiscal Year ended July 31, 1996, compared to fiscal year ended July 31, 1995.

Net sales for the year ended July 31, 1996 increased by 1.5% over fiscal year
1995. The increase was attributable entirely to price increases from
manufacturers being passed on to customers. The volume actually decreased
approximately 1% of sales.

all periods is fairly presented. The following reflects a reclassified
operations statement based on the impact of the inventory defalcation.

- --------------------------------------------------------------------------------
Year Ended July 31,
--------------------------------------
1996 1995 1994
--------------------------------------
000's omitted
- --------------------------------------------------------------------------------
Net Sales $ 501,383 $ 493,827 $ 407,969
- --------------------------------------------------------------------------------
Cost of Sales $ 468,108 $ 460,150 $ 379,839
- --------------------------------------------------------------------------------
Gross Profit $ 33,275 $ 33,677 $ 28,130
- --------------------------------------------------------------------------------
Operating Expenses $ 29,682 $ 29,068 $ 25,561
- --------------------------------------------------------------------------------
Income before defalcation $ 3,593 $ 4,609 $ 2,569
- --------------------------------------------------------------------------------
Inventory defalcation $ 7,400 $ 5,200 $ 2,100
- --------------------------------------------------------------------------------
Net (loss) before income taxes $ (3,807) $ (591) $ (469)
- --------------------------------------------------------------------------------

The Company believes it may have insurance coverage totaling $2,000,000 as a
possible recovery against the inventory defalcation. The Company has not

provided for any recovery in its financial statements for the period ended July
31, 1996, since at this time, such recovery cannot be assured.

The Company has engaged a private contractor to investigate the defalcation and
is cooperating with federal, state and local law enforcement authorities to
determine the source of the defalcation. The Company has also made changes in
personnel and security procedures which it believes will eliminate defalcations
in the future. The Company, upon reconciling its physical inventory for the
fiscal year ended July 31, 1996, believes that no defalcations occurred from the
time of discovery in May 1996 through July 31, 1996.

Gross profit continues to decrease as a result of competitive pressures and a
lower profit on forward buying of pharmaceuticals. A liquidation of LIFO
inventory layers, which were carried at lower costs as compared to current
costs, had the effect of increasing net income by approximately $679,000 for the
year ended July 31, 1996. Had inventories been valued using the first-in,
first-out method, they would have been greater by approximately $4,763,000 at
July 31, 1996 and $10,087,000 at July 31, 1995.

Total expenses for fiscal 1996 increased by 2.1% over such expenses for fiscal
1995. Operating expenses for fiscal 1996, excluding interest expense, increased
by 2% over those for fiscal 1995. The increased operating expenses were caused
by higher paper costs for data processing and professional fees in connection
with a proposed merger of the Company.

The effect of the foregoing factors was that the Company had an increased loss
before taxes of 557%.

Fiscal Year ended July 31, 1995, compared to fiscal year ended July 31, 1994.

Net sales for the year ended July 31, 1995 increased by 21% over fiscal 1994.
The increase was attributable to both an increase in sales volume (approximately
75% of the 21% increase) and an increase in pharmaceutical prices (approximately
25% of the 21% increase).

Gross profit for the year (as restated in the table on page 10 of this Form
10-K) increased by 19.7% over the gross profit for fiscal 1994 (as restated for
inventory defalcation) as a result of the increased sales; however, gross profit
as a percentage of net sales decreased 0.1% from 6.9% to 6.8%, as a result of
competitive pressures and a lower profit on forward buying of pharmaceuticals.

Total expenses for fiscal 1995 increased by 13.7% over such expenses for fiscal
1994. Operating expenses for fiscal 1995, excluding interest expense, increased
by 4.1% over those for fiscal 1994. The increased operating expenses were caused
by higher warehouse labor costs. This was due to higher volume and increased
wages as a result of premium pay for changing to a night shift. Interest costs
were higher because of higher inventory and receivables necessary to support
higher volume as well as higher interest rates.

The effect of the foregoing factors was that the Company had a loss before taxes
for the year ended July 31, 1995 as compared to net income for 1994.

Fiscal Year ended July 31, 1994, compared to fiscal year ended July 31, 1993.

Net sales for the year ended July 31, 1994 increased by 5.3% over fiscal 1993.
The increase was attributable to both an increase in sales volume (approximately
25% of the 5.3% increase) and an increase in pharmaceutical prices
(approximately 75% of the 5.3% increase). The Company believes that part of the
reason why the sales volume increase was so small was due to the poor winter
weather.

Gross profit for fiscal 1994 (as restated in the table on page 10 of this Form
10-K) decreased by 4.2% from the gross profit for fiscal 1993 (as restated for
inventory defalcation). Gross profit as a percentage of net sales decreased from
7.6% to 6.9% as a result of competitive pressures and a lower profit on forward
buying of pharmaceuticals due to smaller price increases.

Total expenses for fiscal 1994 decreased by 2.8% from such expenses for fiscal
1993. Operating expenses, excluding interest expense, for fiscal 1994 decreased
by 2.2% from those for fiscal 1993. The reduced operating expenses were due to
lower maintenance, depreciation and bad debt expense. This reduction in
operating expenses was partially offset by higher professional fees incurred in
connection with the failed negotiations for the acquisition of the Company's
capital stock by Commons Bros. Inc., and Commons Bros. Northeast, Inc. Interest
expense was lower because of reduced borrowing, although this savings was mostly
offset by higher rates.

The effect of the foregoing factors was that the Company's income before
corporate taxes for the year ended July 31, 1994, experienced a 83.5% decrease
from fiscal year 1993. Income taxes for fiscal 1994 were 85.9% lower than in
fiscal year 1993 as a result of the lower income.

Liquidity and Capital Resources. The Company believes that based upon its
current bank agreement it has sufficient liquidity and capital to support future
growth.

Item 8. Financial Statements and Supplementary Data.

See the index constituting a part of Item 14.

Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.

(a) On July 2, 1996, the Executive Committee of Drug Guild Distributors,
Inc. (the "Company") decided to end the engagement of Anchin, Block & Anchin LLP
as the independent auditors of the Company as a result of concerns that the
independence of Anchin, Block & Anchin LLP might be deemed to be impaired by the
Company's investigation of recently discovered defalcations of inventory of the

Company.

The independent auditors' reports on the Company's financial statements
for the past two fiscal years did not contain an adverse opinion or a disclaimer
of opinion and were not qualified or modified as to uncertainty, audit scope or
accounting principles.

The Company believes, and has been advised by Anchin, Block & Anchin LLP
that it concurs in such belief, that during the fiscal years ended July 31, 1994
and July 31, 1995, and from that date to the date of termination of the services
of Anchin, Block & Anchin LLP, the Company and Anchin, Block & Anchin LLP did
not have any disagreement on a matter of accounting principles or practices,
financial statement disclosure or auditing scope or procedure.

(b) On July 11, 1996, the Company engaged Richard A. Eisner & Company, LLP
as its independent auditors to audit the Company's financial statements for the
fiscal year ended July 31, 1996.

(c) This Form 10-K is being filed without reissuing a manually signed
report from the Company's prior accountant for the Company's fiscal years'
ending July 31, 1995 and July 31, 1994. The most recent filing under the
Securities Exchange Act of 1934 (the "Exchange Act") for the aforesaid report is
the Form 10-K Report for fiscal year ended July 31, 1995.

The prior accountants, Anchin Block & Anchin LLP, have refused to provide
such reissued manually signed report due to their concern that they have lost
their independence as auditors because of potential claims against Anchin Block
& Anchin LLP by the Company as a result of the inventory defalcations discovered
in May of 1996 (discussed elsewhere in this report) and which relate to each of
the three fiscal years of the Company ended July 31, 1996.

There can be no assurance that Anchin Block & Anchin would issue the
report in its original form and without qualification if the aforesaid concern
regarding their independence was resolved.

The Company has inquired of Anchin Block & Anchin LLP whether investors
should be advised that the previously issued report has been withdrawn and
cannot be relied upon. Anchin Block & Anchin LLP has responded that the report
should not be withdrawn.

PART III

Item 10. Directors and Executive Officers of the Registrant.

The officers of the Company during the fiscal year ended July 31, 1996 were:

Name Age Position
---- --- --------
Alfred Hertel 67 Chairman of the Board
Roman Englander 67 President and Chief Executive Officer
Alan Glenn 66 Senior Vice President and Chief
Operating Officer and President
Gary Merten 46 Vice President - Data Processing
Mark Englander 40 Vice President
Norman Genzer 54 Vice President
Jay Reba 55 Vice President - Finance
Martin Shapiro 65 Secretary - Treasurer

The Company's officers hold office until the next annual meeting of the
Company's Board of Directors and until their respective successors are elected.

For more than the previous five years, Mr. Hertel has been an officer and
a principal shareholder of Oakland Drug Inc., located in Oakland, New Jersey.

Mr. Roman Englander has been employed by the Company since 1949. He has
functioned as the chief executive of the Company since 1970 and has been
President since 1973. Mr. Englander is the father of Mark Englander. Mr.
Englander's term as director expires in 1998. Mr. Englander retired as president
and chief executive of the Company on December 31, 1995.

Mr. Glenn was appointed President of the Company in March 1996. He became
a Vice President in 1973; Senior Vice President in 1980; and Chief Operating
Officer in 1995. Prior thereto and for more than 25 years, he was a principal of
Ritz Drugstores, which operates in New Jersey. Mr. Glenn retired as President of
the Company on August 31, 1996.

Mr. Merten has been employed by the Company since 1978 in the data
processing area and has been a Vice President since October, 1981. Mr. Merten
resigned from the Company on February 13, 1996.

Mr. Mark Englander has been employed by the Company since 1979. He has
been a Vice President since 1986. He is the son of Roman Englander.

Mr. Genzer has been employed by the Company since 1982. He has been a Vice
President since 1986.

Mr. Reba has been employed by the Company since 1987. From August of 1987

to December of 1991 he was employed as Controller. He has been Vice President -
Finance since December, 1991.

Mr. Shapiro was a principal of Franhill Drugs in Hollis, New York for more
than five years preceding 1983 and a consultant to the Company from 1983 to
1986. His term as a director expired in 1987.

All of the officers, except Mr. Hertel, are full time employees of the
Company. Mr. Hertel is not an employee of the Company, he does not devote a
significant portion of his time to his duty as Chairman of the Board, and he
receives no cash remuneration for serving as Chairman of the Board.

At the annual meeting of shareholders of the Company, approximately
one-third of the members of the Board of Directors are elected for three year
terms.

The following table sets forth the names of the directors of the Company
and, as to each director, the year in which each began as director and the
number and percentage of outstanding shares of Common Stock and Preferred Stock
of the Company owned by him. The table also contains information as to the
ownership of such Common Stock and Preferred Stock by the officers of the
Company who own such securities and by all officers and directors as a group.

Common Stock Preferred Stock
of the Company of the Company
Owned Beneficially Owned Beneficially
at July 31, 1996(2) at July 31, 1996
------------------- ----------------
Director Number Percent Number Percent
Name Since of Shares of Class of Shares of Class
- ---- ----- --------- -------- --------- --------
Harold Blumenkrantz (1) 1981 36,685 .37 975.92 3.77
Marco Cutinello 1992 -- -- -- --
Louis Del Rosso 1986 30,791 .31 -- --
Herbert Dudak 1986 96,578 .96 298.10 1.11
Harold Eckstein 1983 217,563 2.17 -- --
Paul Emanuel 1985 24,480 .24 -- --
Roman Englander 1976 339,851 3.39 -- --
Hal Epstein 1987 46,008 .46 -- --
Peter Esposito 1991 13,242 .13 -- --
Sidney Falow 1979 24,740 .25 -- --
Sanford Fishman 1976 93,705 .93
Herbert Gordon 1995 123,403 1.23 -- --
Gerald Ginsberg 1978 222,346 2.21 -- --
George Grumet 1988 47,935 .48 2,321.10 8.96
Alfred Hertel (1) 1976 113,358 1.13 -- --
Steven J. Kabakoff 1989 50,999 .51 -- --
Michael Katz 1976 101,196 1.01 -- --
Jay Kessler 1986 112,231 1.12 -- --

Gerald Koblin 1995 43,997 .44 -- --
Jerry Koizim 1988 23,398 .23 -- --
Anthony Kranjac 1992 58,820 .59 -- --
Ely Krellenstein 1976 206,323 2.06 -- --
John Lynch (1) 1976 289,162 2.88 -- --
George Manolakis 1983 108,456 1.08 -- --
Boris Mantell 1991 45,026 .45 -- --
Richard Rostholder 1988 334,394 3.34 -- --
Bipinchandra Shah 1987 137,790 1.37 669.6 2.59
Murray Shapiro 1976 27,891 .28 -- --
Howard Sternheim (1) 1976 661,946 6.60 -- --

(Table continued)
Common Stock Preferred Stock
of the Company of the Company
Owned Beneficially Owned Beneficially
at July 31, 1996(2) at July 31, 1996
------------------- ----------------
Director Number Percent Number Percent
Name Since of Shares of Class of Shares of Class
- ---- ----- --------- -------- --------- --------

Alan Traster 1989 124 ,576 1.24 -- --
Ernest Wyre(1) 1976 149,669 1.49 -- --

Total of All
Officers and Directors
as a group (37 persons) 3,987,049 39.76 4,255.7 16.43

The following table sets forth the names of the directors of the Company who
have subscribed for but have not purchased shares of Common Stock of the
Company. The table also contains information as to outstanding subscriptions for
all officers and directors as a group.

Shares of Common Stock Shares of Common Stock
Subscribed for but Unissued to be Issued Within 60-day
as of period following
Name July 31, 1996(2) July 31, 1996
- ---- ---------------- -------------

Hal Epstein 10,452 581
Anthony Kranjac 5,226 1,161
Richard Rostholder 7,742 774
Bipinchandra Shah 24,774 3,097
Murray Shapiro 7,161 387
Howard Sternheim (1) 101,032 5,613
Alan Traster 64,452 6,968

Total of All Officers and

Directors as a group
(37 persons) 220,839 18,581

- ----------
(1) Member of the Executive Committee of the Board of Directors.

(2) Includes shares of Common Stock to be issued within the 60 day period
following July 31, 1996. Upon the payment of amounts due on the monthly
subscriptions, "Shares of Common Stock Subscribed for but Unissued" column
will be reduced by the shares issued.

Terms Expiring in 1999

Mr. Blumenkrantz, age 58, has been a principal of West End Family
Pharmacy, Inc., Long Branch, New Jersey since 1962. Mr. Falow, age 65, has for
more than the past five years been owner of Weber's Pharmacy in Brooklyn, New
York. Mr. Kabakoff, age 49, has for more than the past five years been a
director, Vice President and Secretary of Kasbil Corporation, Bronx, New York,
which does business as Sol's Health & Beauty. Mr. Kabakoff has also been a
director of Bronx Frontier, Inc., Bronx, New York, since 1988 and was a director
and secretary of Best Alarm Company, Bronx, New York, from 1989 to 1991. Mr.
Katz, age 57, who was a principal of Katz Drug, Brooklyn, New York for more than
five years preceding 1994, is now retired. Mr. Kranjac, age 58, has been a
principal of Medical Pharmacy, Queens, New York, for more than the past five
years. Mr. Lynch, age 54, has been a principal of Bach's Drug Store,
Hackettstown, New Jersey since 1962. Mr. Manolakis, age 61, has for more than
the past five years been the owner of Oakhurst Pharmacy of Oakhurst, New Jersey,
and since 1992, the Westpark Pharmacy. Mr. Rostholder, age 42 has for more than
five years been a principal of Franhill Drugs, Inc., Hollis, New York. Mr.
Shapiro, age 57, was a principal of Core Software Solutions, Inc. from April,
1991 to March, 1992, was a principal of S & A Pharmacy, Bronx, New York, from
prior to five years ago until September 1990, and has been employed as general
manager of Zitomer Pharmacy, Inc. from March, 1992 to the present. Mr. Traster,
age 47, has for more than the five years been President, Chief Operating Officer
and a director of 17 Wanaque Corp. Saxon West, Inc. and Pompton Nursing Home
Suppliers, Inc., all with a principal address at Pompton Lakes, New Jersey.

Terms Expiring in 1998

Mr. Cutinello, age 63, has been a principal of Rita Pharmacy, Roselle, New
Jersey for more than five years. Mr. Del Rosso, age 51, has been a principal of
Investra Pharmacy, Summit, New Jersey, for more than five years. Mr. Dudak, age
64, has been a principal of Codumel Pharmacy, Brooklyn, New York, for more than
five years. Mr. Englander, age 67, who was President and Chief Executive Officer
of the Company for more than the past five years, is now retired. Mr. Fishman,
age 61, has been a principal of Fishman's Bond Drugs, Inc. of Jersey City, New
Jersey, for more than five years. Mr. Grumet, age 54, has been for more than
five years the owner of Thrifty Drug, Piscataway, New Jersey, and a principal of
Keansburg Drugs, Keansburg, New Jersey. Mr. Hertel, age 67, has, since prior to

1967, been a principal of Brittany Chemists, Inc. in New York City and Oakland
Drugs, Oakland, New Jersey. Mr. Mantell, age 50, for more than five years, has
been President of Globe Drug Corp. d/b/a Claremont Chemists, New York, New York,
served as Secretary of Magle Drug Corp., d/b/a Perry Drugs, Brooklyn, New York
from 1987 to 1992, has, since 1988, been Vice President of Brothers Drug Corp.,
d/b/a Variety Drugs, Jamaica, New York and has, since 1990, been President of
First Elm Drug Corp., d/b/a Elm Drugs, New York, New York. Mr. Sternheim, age
64, has, for more than the past five years been President and principal
shareholder of Vanderveer Pharmacy, Inc. in Brooklyn, New York and twenty-one
(21) other drug stores and one (1) variety store in the New York City area. Mr.
Wyre, age 72, who was a principal of Lenox Terrace Drug Store, Inc. in Brooklyn,
New York, for more than five years preceding 1987, is now a private investor.

Terms Expiring in 1997

Mr. Eckstein, age 65, has been the owner of Leff Drugs, Bronx, New York
for more than the past five years. Mr. Emanuel, age 70 has been the owner of
Town and Country Pharmacy, Inc., Ridgewood, New Jersey, for more than five
years. Mr. Epstein, age 46, has for more than five years been a principal in
Thriftway Staten Island Drug Corp., Staten Island, New York, Thriftway Cross
County Drug Corp., Yonkers, New York, Thriftway Lawrence Drug Corp., Lawrence,
New York and since November, 1991, in four additional Thriftway stores including
the Thriftway Concourse Drug Corp., Bronx, New York. Mr. Esposito, age 50, has
for more than the past five years been the President and owner of E&W Drug
Corp., Edison, New Jersey, E&W of Union, Inc., Union, New Jersey and has been
President and an owner of E&M Pharmacies, Inc., New Brunswick, New Jersey. All
three corporations are doing business as Metro Drugs. Mr. Ginsberg, age 68, has
for more than five years been President of C. O. Bigelow Chemists, Inc., and
C.O. Bigelow of Roosevelt, Inc. in New York City. Mr. Gordon, age 62, has been a
principal of Webster Drug and Cosmetic Corp., Bronx, New York for more than five
years. Mr. Kessler, age 58, has been a principal of Ark Drugs, Brooklyn, New
York for more than five years. Mr. Koblin, age 59, has been a principal of
Koblin Pharmaceuticals, Inc., Nyack, New York for more than five years. Mr.
Koizim, age 69, has been a principal of Drug Fair, Kearny, New Jersey, for more
than five years. Mr. Krellenstein, age 68, was a principal of Oval Drug Co.,
Bronx, New York, between 1989 and 1991; he has since retired. Mr. Shah, age 52,
has been President of V and B Drug Corp., Bronx, New York for more than five
years.

Item 11. Executive Compensation.

Summary Compensation Table

The following table sets forth, for the fiscal years ended July 31, 1996,
1995 and 1994, the cash compensation paid by the Company, as well as certain
other compensation paid with respect to those years, to the chief executive
officer and each of the four other most highly compensated executive officers of
the Company in all capacities in which they served.

Annual Compensation
----------------------------------------
Other
Name Annual All Other
and Principal Compen- Compen-
Position Year Salary Bonus sation sation(1)
- --------------------------------------------------------------------------------
Roman Englander 1996 $272,198.00 -- -- $10,327.00
President and 1995 $526,400.00 -- -- $10,320.00
CEO(2) 1994 $448,716.00 -- -- $ 9,007.00

Alan Glenn 1996 $202,800.00 -- -- $ 3,064.00
Senior Vice 1995 $202,800.00 -- -- $ 2,870.00
President, COO 1994 $202,000.00 -- -- $ 6,309.00
and President(3)

Gary Merten 1996 $ 88,500.00 -- -- --
Vice President 1995 $125,800.00 -- -- --
Date Processing(4) 1994 $126,100.00 -- -- --

Jay Reba 1996 $107,600.00 -- -- --
Vice President 1995 $107,600.00 -- -- --
Finance 1994 $106,900.00 -- -- --

Mark Englander 1996 $106,000.00 -- -- --
Vice President 1995 $105,500.00 -- -- --
1994 $105,300.00 -- -- --

Norman Genzer 1996 $105,500.00
Vice President 1995 $108,000.00 -- -- --
1994 $105,300.00 -- -- --

All Executive Officers
as a Group (8 persons) $953,198.00 -- -- $13,391.00

- ----------
(1) Value of insurance premiums paid by the Company during the covered
fiscal year with respect to term life insurance for the benefit of the named
executive officer.

(2) Retired effective December 31, 1995.

(3) Appointed President of the Company in March 1996. Retired from the
Company effective August 31, 1996.

(4) Resigned from the Company on February 13, 1996.

Mr. Englander entered into a Resignation Agreement with the Company dated
December 5, 1995 which, among other things (i) accepts the resignation of Mr.
Englander as President and Chief Executive Officer effective December 31, 1995;
(ii) employs Mr. Englander as a consultant to the Company from January 1, 1996
through September 30, 1996; and (iii) ratifies and confirms a Deferred
Compensation provision of an Employment Agreement between the Company and Mr.
Englander dated as of October 1, 1993 whereby the Company shall pay Englander,
commencing upon the earlier of Englander's attaining age 65 or the date of
termination of his employment, additional compensation payable in one hundred
twenty (120) equal monthly installments of Eight Thousand Three Hundred
Thirty-Three Dollars and Thirty-Four Cents ($8,333.34) each. See also Note F of
"Notes to the Financial Statements."

None of the directors or members of the Executive Committee, except Mr.
Englander, receives any direct remuneration from the Company, but the Company
pays the premium for term life insurance policies covering most of them with the
benefits of $100,000 each payable to their designees. The aggregate annual
premium for these policies is approximately $49,000.

Although most of the directors are affiliated with certain customers of
the Company, all transactions between such customers and the Company are in its
normal course of business and these customers by virtue of being affiliated with
directors receive no preferences as to price or other terms and conditions at
which they buy products from the Company.

The Company has a non-contributory, defined benefit pension plan for
non-union employees, including its officer-employees, to which it contributed,
with respect to such officer-employees, an aggregate of approximately $105,600
for the fiscal year ended July 31, 1996. See Note F of "Notes to the Financial
Statements." Under the plan, participating employees upon reaching age 65 after
5 years of plan membership are entitled to annual retirement benefits in
accordance with the following formula: (a) 30% (reduced by 3/4% for each year or
part thereof less than 40 years employed by the Company) of average yearly
compensation during the five consecutive years of the last ten years during
which the employee received the highest compensation ("Yearly Base
Compensation") plus (b) 18.72% of the excess of Yearly Base Compensation over
1992 Social Security covered compensation, such 18.72% reduced by .65% for each
year under 32 years employed by the Company. The plan provides for related
benefits in the event of death, disability or early retirement. An employee's
interest in the plan becomes fully vested in increments over his first five
years of membership in the plan.

Defined Benefit or Actuarial Plan Disclosure

Years of Service
Remuneration 15 20 25 30 35
- -------------------------------------------------------------------------------

$100,000 $18,000 $24,000 $30,000 $36,000 $42,000

$125,000 $23,000 $30,000 $38,000 $45,000 $53,000
$150,000 + $28,000 $37,000 $46,000 $54,000 $60,000

The estimated credit years of service for each of the executive officers
named in the "Summary Compensation Table" as of January 1, 1996, are as follows:

Name Estimated Credited Years
---- ------------------------

Roman Englander 46
Alan Glenn 21
Gary Merten 17
Jay Reba 8
Mark Englander 15
Norman Genzer 10

The form of the pension plan is a life annuity with 10 years guaranteed.
There is no deduction for Social Security or other offset amounts.

The Board of Directors of the Company unanimously agreed at a meeting of
the Board of Directors to freeze the Company's contribution to the pension plan
as of June 28, 1996.

The Company also has a profit-sharing plan, including a 401(k), for
non-union employees, including its officer-employees, which requires no fixed or
minimum contribution. There was no contribution to the profit-sharing plan for
the fiscal years ended July 31, 1996 and 1995. Under the plan, contributions by
the Company are allocated among the accounts of participating employees in
proportion to their respective compensations, as defined. Upon retirement, death
or disability, participating employees are entitled to the value of their
accounts as provided in the plan. An employee's interest in the plan becomes
vested in increments over the first five years of his membership.

Item 12. Security Ownership of Certain Beneficial Owners and Management

To the knowledge of the Company, no person owns beneficially or of record
more than 5% of any class of the Company's voting securities except for:

(1) (2) (3) (4)
Title of Name and Address Amount of Shares and Nature Percent
Class of beneficial owner of Beneficial Ownership of Class
- -------- ------------------- ----------------------- --------

Preferred John Hoover 2,065.9 7.98%

Stock 714 North Market Street
Cortez, Co 81321

Maurice Malin 2,166.1 8.37%
45 Hall Place
Tappan, New York 10983

George Grumet 2,321.1 8.96%
17 Phillips Road
Edison, New Jersey 08816

Common Howard Sternheim 661,946 6.60%
Stock 1020 Park Avenue
New York, NY 10028

Item 13. Certain Relationships and Related Transactions.

None

Item 14. Exhibits, Financial Statements, Financial Statement
Schedules and Reports on Form 8-K

(a)(1) Financial Statements.

The following are filed with this report:

i) Independent Auditor's Report.

ii) Balance Sheets at July 31, 1996 and 1995.

iii) Statements of Operations for the years ended July 31, 1996, 1995 and
1994.

iv) Statements of Stockholders' Equity for the years ended July 31,
1996, 1995 and 1994.

v) Statements of Cash Flow for the years ended July 31, 1996, 1995 and
1994.

vi) Notes to the Financial Statements.

(a)(2) Financial Statement Schedules:

i) Schedules II - Valuation and Qualifying Accounts

(a)(3) Exhibits.

The following exhibits are filed as part of this report:

Page No. In
Sequential
Exhibit Numbering
Number System
- ------- -----------

3(a) Certificate of Incorporation of the Registrant, filed
July 22, 1976 and Amendments to Certificate of
Incorporation [3(a)](6)

(b) Registrant's By-laws and Amendments thereto [3(b)](6)

(d) Amendment to By-Laws

4(a) Common Stock Subscription Agreement (9)

4(b) Preferred Stock Subscription Agreement (9)

(d) Special Common Stock Subscription Agreement [4(b)](4)

(e) Special Common Stock Subscription Agreement Modified
as of January 15, 1988 [4(c)](5)

(f) Variable Rate Promissory Note Subscription Agreement
[4(c)](4)

(g) Form of Variable Rate Promissory Note [4(d)](1)

(h) Form of Old Common Stock Certificate [4(e)](3)

Page No. In
Sequential
Exhibit Numbering
Number System
- ------- -----------

(i) Form of Special Common Stock Certificate [4(f)](3)

(j) Special Common Stock Subscription Agreement modified
as of June, 1989 [4(h)](6)

(k) Form of Common Stock Certificate [4(k)](8)

(1) Form of Preferred Stock Certificate [4(l)](8)

(m) Revised Common Stock Subscription Agreement (10)

(The Registrant will furnish the Securities and
Exchange Commission upon request a copy of each
instrument defining the rights of the holders of the
Registrant's long term debt)

10(a) Lease, dated September 13, 1973, between the
Registrant and Hartz Mountain Industries, Inc., as
amended November 19, 1980 and December 28, 1981
[5(b)](2)

(b) Employment Agreement, dated as of December 19, 1985,
between the Registrant and Roman Englander [5(b)](5)

(d) Profit Sharing Plan [10(d)](3)

(e) Amendment, dated as of February 23, 1989, to Accounts
Financing Agreement dated March 24, 1980, as amended,
between the Registrant and Bankers Trust Company
[10(e)](7)

(f) Lease, dated December 15, 1989, between the
Registrant and Hartz Mountain Industries, Inc.
[10(f)](7)

Page No. In
Sequential
Exhibit Numbering
Number System
- ------- -----------

10(g) Documents Further Amending Accounts Financing
Agreement, dated March 24, 1980, as amended, between
Registrant and Bankers Trust Company (10)

(h) Sublease, dated June 10, 1992 between Hoogovens
Aluminum Corporation, Sublessor, and Drug Guild
Distributors, Inc., Sublessee, and related documents
(11)

(i) Employment Agreement dated as of October 1, 1993
between the Registrant and Roman Englander (12)

(j) Agreement dated July 6, 1993 between the Registrant
and Joseph B. Churchman (12)

(k) Amended and Restated Drug Guild Distributors, Inc.
Profit Sharing Plan and Trust effective August 1,
1989 and the Amendment thereto dated 9/1/94

(l) Amended and Restated Drug Guild Distributors, Inc.
Pension Plan effective January 1, 1989 and the
Amendment thereto dated 9/1/94

(m) Resignation Agreement between the Company and Roman
Englander dated December 5, 1996.

(n) Indemnification Agreement between the Company and
Joseph B. Churchman dated June 18, 1996.

(o) Agreement and Plan of Merger by and among the Company
Neuman Distributors, Inc. and Neuman Health Services,
Inc. dated as of October 25, 1996.

11 Computations of Earnings per Share

12(a) Statement or Computation of ratios (13)

- ----------

(1) Incorporated by reference to the specified exhibit constituting a part of
the Company's Notification on Form 1-A (File No. 24 NY-8317)

(2) Incorporated by reference to the specified exhibit constituting a part of
the Company's Notification on Form 1-A (File No. 24 NY-8303)

(3) Incorporated by reference to the specified exhibit constituting a part of
the Company's Registration Statement on Form S-18 (File No. 2-85967-NY)

(4) Incorporated by reference to the specified exhibit constituting a part of
the Company's Registration Statement on Form S-18 (File No. 2-96510-NY)

(5) Incorporated by reference to the specified exhibit constituting a part the
Company's Notification on Form 1-A (File No. 24-NY-8736)

(6) Filed as the specified exhibit to the Company's Registration Statement on
Form S-4 (File No. 33-35396)

(7) Filed as the specified exhibit to Amendment No. 1 to the Company's
Registration Statement on Form S-4 (File No. 33-35396).

(8) Filed as the specified exhibit to the Company's Registration Statement on
Form S-2 (File No. 33-40277).

(9) Filed as to specified exhibit constituting a part of the Registrant's Form
10-K, Annual Report, pursuant to Section 13 or 15(D) of the Securities
Exchange Act of 1934, for the fiscal year ended July 31, 1991.

(10) Filed as the Specified Exhibit to Post-Effective Amendment No.1 to the
Company's Registration Statement on Form S-2 (File No. 33-40277).

(11) Filed as to specified exhibit constituting a part of the Registrant's Form
10-K, Annual Report, pursuant to Section 13 or 15(D) of the Securities
Exchange Act of 1934, for the fiscal year ended July 31, 1992.

(12) Filed as to specified exhibit constituting a part of the Registrant's Form
10-K, Annual Report, pursuant to Section 13 or 15(D) of the Securities
Exchange Act of 1934, for the fiscal year ended July 31, 1993.

(13) Filed herewith.

(b)Reports on Form 8-K

A Form 8-K was filed with the Securities and Exchange Commission ("SEC")
on August 9, 1996 and thereafter amended by a Form 8-K/A filed with the SEC on
August 23, 1996 719-3

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the Registrant
has duly caused this Section 13 or 15(d) report to be executed on its behalf by
the undersigned, thereunto duly authorized, in the City of Secaucus, State of
New Jersey, on November 8, 1996.

DRUG GUILD DISTRIBUTORS, INC.

By: /s/ Alfred W. Hertel
-------------------------------------------------
Alfred Hertel, Chairman of the Board of Directors

Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed by the following persons on behalf of the Registrant and
in the capacities and on the dates indicated.

Signature Title Date
- --------- ----- ----

/s/ Jay Reba Vice President, Principal November 8, 1996
- --------------------------- Financial and
Jay Reba Accounting Officer

/s/ Harold Blumenkrantz Director November 8, 1996
- ---------------------------
Harold Blumenkrantz

___________________________ Director November 8, 1996
Marco N. Cutinello

/s/ Louis J. DelRosso Director November 8, 1996
- ---------------------------
Louis J. Del Rosso

Signature Title Date
- --------- ----- ----

/s/ Herbert Dudak Director November 8, 1996

- ---------------------------
Herbert Dudak

/s/ Harold Eckstein Director November 8, 1996
- ---------------------------
Harold Eckstein

/s/ Paul Emanuel Director November 8, 1996
- ---------------------------
Paul Emanuel

/s/ Roman Englander Director November 8, 1996
- ---------------------------
Roman Englander

___________________________ Director November 8, 1996
Hal Epstein

/s/ Peter Esposito Director November 8, 1996
- ---------------------------
Peter Esposito

/s/ Sidney Falow Director November 8, 1996
- ---------------------------
Sidney Falow

/s/ Sanford Fishman Director November 8, 1996
- ---------------------------
Sanford Fishman

Signature Title Date
- --------- ----- ----

___________________________ Director November 8, 1996
Gerald Ginsberg

/s/ Herbert Gordon Director November 8, 1996
- ---------------------------
Herbert Gordon

/s/ George Grumet Director November 8, 1996
- ---------------------------
George Grumet

/s/ Alfred W. Hertel Director November 8, 1996
- ---------------------------
Alfred Hertel

/s/ Steven J. Kabakoff Director November 8, 1996
- ---------------------------
Steven J. Kabakoff

___________________________ Director November 8, 1996
Michael Katz

/s/ Jay Kessler Director November 8, 1996
- ---------------------------
Jay Kessler

/s/ Jerry Koblin Director November 8, 1996
- ---------------------------
Jerry Koblin

Signature Title Date
- --------- ----- ----

____________________________ Director November 8, 1996
Jerry Koizim

____________________________ Director November 8, 1996
Anthony Kranjac

____________________________ Director November 8, 1996
Ely Krellenstein

____________________________ Director November 8, 1996
John Lynch

/s/ George Manolakis Director November 8, 1996
- ---------------------------
George Manolakis

/s/ Boris Mantel Director November 8, 1996
- ---------------------------
Boris Mantel

___________________________ Director November 8, 1996
Richard Rostholder

/s/ Bipinchandra Shah Director November 8, 1996
- ---------------------------
Bipinchandra Shah

Signature Title Date
- --------- ----- ----

/s/ Murray Shapiro Director November 8, 1996
- ---------------------------
Murray Shapiro

/s/ Howard Sternheim Director November 8, 1996
- ---------------------------
Howard Sternheim

___________________________ Director November 8, 1996
Alan D. Traster

___________________________ Director November 8, 1996
Ernest Wyre

DRUG GUILD DISTRIBUTORS INC.

EARNINGS TO FIXED CHARGES (S-K Item 503(d))

Year Ended July 31

1996 1995 1994
- --------------------------------------------------------------------------------

(000's omitted except Ratio-Earnings to Fixed Charges)

Pretax Income $(3,807) $ (591) $ (469)

Interest Expense $ 5,494 $ 5,327 $ 2,915

Total $ 1,687 $ 4,736 $ 3,384

Interest Expense $ 5,494 $ 5,327 $ 2,915

Ratio-Earnings to
Fixed Charges 0.31 0.89 1.16

Pro Forma Calculations under Regulation S-K Item 503(d)9 are not required
because the contemplated preferred stock dividends are payable in stock instead
of cash.

DRUG GUILD DISTRIBUTORS, INC.

INDEX TO FINANCIAL STATEMENTS AND SCHEDULES

FILED WITH THE ANNUAL REPORT OF THE COMPANY ON FORM 10-K

PAGE
NUMBER
------
PART II ITEM 8:

REPORT OF INDEPENDENT AUDITORS F-2

BALANCE SHEETS AS AT JULY 31, 1996
AND JULY 31, 1995 F-3

STATEMENTS OF OPERATIONS FOR THE YEARS
ENDED JULY 31, 1996, JULY 31, 1995 AND
JULY 31, 1994 F-4

STATEMENTS OF STOCKHOLDERS' EQUITY FOR
THE YEARS ENDED JULY 31, 1996, JULY 31,
1995 AND JULY 31, 1994 F-5

STATEMENTS OF CASH FLOWS FOR THE YEARS
ENDED JULY 31, 1996, JULY 31, 1995
AND JULY 31, 1994 F-6

NOTES TO FINANCIAL STATEMENTS F-7

PART IV ITEM 14:

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
FOR THE YEARS ENDED JULY 31, 1996, JULY 31, 1995
AND JULY 31, 1994 F-19

EXHIBIT 11 - COMPUTATION OF EARNINGS PER SHARE F-20

F-1

REPORT OF INDEPENDENT AUDITORS

Board of Directors and Stockholders
Drug Guild Distributors, Inc.
Secaucus, New Jersey

We have audited the accompanying balance sheet of Drug Guild Distributors,
Inc. as at July 31, 1996 and the related statements of operations, stockholders'
equity and cash flows for the year then ended. These financial statements are
the responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audit.

We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements enumerated above present fairly,
in all material respects, the financial position of Drug Guild Distributors,
Inc. at July 31, 1996, and the results of its operations and its cash flows for
the year then ended, in conformity with generally accepted accounting
principles.

As described in Note O, during 1996 the Company discovered an inventory
defalcation affecting 1996 and prior years. Management estimates the loss for
1996 to be approximately $7,400,000.

The audit above includes Schedule II, for the year ended July 31, 1996. In
our opinion, the schedule referred to above presents fairly the information set
forth therein in conformity with the applicable accounting regulation of the
Securities and Exchange Commission.

New York, New York
October 14, 1996

F-2

DRUG GUILD DISTRIBUTORS, INC.

BALANCE SHEETS
(in thousands, except per share data)

July 31,
---------------------
ASSETS 1996 1995
--------- ---------

Current assets:
Cash .......................................................... $ 200 $ 2,023
Trade receivables - stockholders .............................. 27,913 26,536
Trade receivables - nonstockholders ........................... 39,361 36,713
Allowance for doubtful accounts ............................... (1,203) (1,123)
Merchandise inventory ......................................... 29,440 38,896
Deferred income tax benefit ................................... 788
Tax refund receivable ......................................... 1,036
Prepaid expenses and other current assets ..................... 805 791
--------- ---------
Total current assets ................................... 97,552 104,624
--------- ---------
Property and equipment, net ...................................... 3,331 3,341
--------- ---------
Other assets:
Trade receivables, noncurrent portion - stockholders .......... 1,593 2,161
Trade receivables, noncurrent portion - nonstockholders ....... 2,288 2,914
Allowance for doubtful accounts ............................... (438) (460)
Deferred income tax benefit ................................... 1,426 246
Other assets .................................................. 222 440
--------- ---------
Total other assets ..................................... 5,091 5,301
--------- ---------

T O T A L .............................................. $ 105,974 $ 113,266
========= =========

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Loans payable - bank .......................................... $ 53,104 $ 53,175
Notes and loans payable ....................................... 527 772
Accounts payable .............................................. 34,590 37,463
Accrued expenses and taxes .................................... 1,475 1,832
--------- ---------
Total current liabilities .............................. 89,696 93,242
--------- ---------
Long-term liabilities:
Notes payable ................................................. 237 501
Deferred rent payable ......................................... 263

Deferred compensation payable ................................. 570 623
--------- ---------
Total long-term liabilities ............................ 1,070 1,124
--------- ---------
Total liabilities ...................................... 90,766 94,366
--------- ---------
Redeemable preferred stock:
Authorized 250,000 shares, $100 par value; issued and
outstanding - 26,000 and 39,000 shares ...................... 2,589 3,933
--------- ---------
Stockholders' equity:
Common stock, authorized 25,000,000 shares, $1 par value;
issued and outstanding - 10,023,000 and
10,000,000 shares ........................................... 10,023 10,000
Subscribed and unissued - 412,000 and 425,000 shares .......... 412 425
Additional paid-in capital .................................... 3,628 3,792
Retained earnings ............................................. (805) 1,650
--------- ---------
Total before subscriptions receivable .................. 13,258 15,867

Less subscriptions receivable ................................. 639 900
--------- ---------
Total stockholders' equity ............................. 12,619 14,967
--------- ---------

T O T A L .............................................. $ 105,974 $ 113,266
========= =========

Attention is directed to the foregoing accountants' report and to the
accompanying notes to financial statements.

F-3

DRUG GUILD DISTRIBUTORS, INC.

STATEMENTS OF OPERATIONS
(in thousands, except per share data)

Year Ended July 31,
---------------------------------
1996 1995 1994
--------- --------- ---------
Net sales:
Stockholders ........................ $ 209,428 $ 206,271 $ 199,905
Nonstockholders ..................... 291,955 287,556 208,064
--------- --------- ---------
Total net sales .............. 501,383 493,827 407,969

Cost of sales .......................... 468,108 465,350 381,939
Estimated loss on defalcation (Note O) 7,400
--------- --------- ---------

Gross profit ........................... 25,875 28,477 26,030
--------- --------- ---------

Operating expenses:
Warehouse ........................... 8,886 8,822 8,036
Shipping and delivery ............... 5,674 5,783 5,709
Selling, general and administrative 10,229 9,682 9,592
Interest expense .................... 5,494 5,327 2,915
Interest (income) ................... (601) (546) (691)
--------- --------- ---------

Total operating expenses ..... 29,682 29,068 25,561
--------- --------- ---------

Income (loss) before income taxes ...... (3,807) (591) 469
--------- --------- ---------

Provision (benefit) for income taxes:
Current ............................. (1,151) (94) 305
Deferred ............................ (392) 8 (144)
--------- --------- ---------

T o t a l .................... (1,543) (86) 161
--------- --------- ---------

NET INCOME (LOSS) ..................... (2,264) (505) 308

Less:
Stock dividend on special common
stock ............................. 67
Stock dividend on preferred stock ... 191 291 413
--------- --------- ---------

NET (LOSS) ATTRIBUTABLE TO COMMON
STOCKHOLDERS ........................ $ (2,455) $ (796) $ (172)
========= ========= =========

(LOSS) PER COMMON SHARE ................ $ (0.24) $ (0.08) $ (0.01)
========= ========= =========

Attention is directed to the foregoing accountants' report and to the
accompanying notes to financial statements.

F-4

DRUG GUILD DISTRIBUTORS, INC.

STATEMENTS OF STOCKHOLDERS' EQUITY
(in thousands)

Common Stock $1 Par Value
------------------------------------
Issued and Subscribed and
Outstanding Unissued Additional
----------------- ---------------- Paid-in Retained
Shares Amount Shares Amount Capital Earnings
------ ------ ------ ------ ------- --------

Balance - July 31, 1993.......................................... 9,448 $ 9,448 1,123 $1,123 $3,886 $ 2,618

Transactions for the year ended July 31, 1994:
Net income.................................................... 308
Common stock redeemed or cancellations........................ (14) (14) (38) (38) (35)
Common stock to offset accounts receivable .................. (79) (79) (42)
Collections on subscriptions.................................. 482 482 (482) (482)
Stock dividend on special common stock paid-in common stock .. 46 46 21 (67)
Stock dividend on preferred stock ............................ (413)
Common stock subscription adjustments ........................ 67 67 95
Preferred stock cancellations ................................ 2
------- -------- ------ ------- ------- --------

Balance - July 31, 1994.......................................... 9,883 9,883 670 670 3,927 2,446

Transactions for the year ended July 31, 1995:
Net (loss).................................................... (505)
Common stock redeemed or cancellations........................ (19) (19) (64) (64) (5)
Common stock to offset accounts receivable.................... (111) (111) (64)
Collections on subscriptions.................................. 247 247 (247) (247)
Stock dividend on preferred stock ............................ (291)
Common stock subscription adjustments ........................ 66 66 (66)
------- -------- ------ ------- ------- --------

Balance - July 31, 1995.......................................... 10,000 10,000 425 425 3,792 1,650

Transactions for the year ended July 31, 1996:
Net (loss).................................................... (2,264)
Common stock redeemed or cancellations........................ (1) (1) (18)
Common stock to offset accounts receivable.................... (98) (98) (37)
Collections on subscriptions.................................. 121 121 (121) (121)
Stock dividend on preferred stock ............................ (191)
Common stock subscription adjustments ........................ 109 109 (109)
------- -------- ------ ------- ------- --------

BALANCE - JULY 31, 1996.......................................... 10,023 $10,023 412 $ 412 $3,628 $ (805)
======= ======== ====== ======= ======= ========

Total Before Less Total
Subscriptions Subscriptions Stockholders'
Receivable Receivable Equity
------------- ------------- -------------

Balance - July 31, 1993.......................................... $17,075 $2,356 $14,719

Transactions for the year ended July 31, 1994:
Net income.................................................... 308 308
Common stock redeemed or cancellations........................ (87) (69) (18)
Common stock to offset accounts receivable .................. (121) (121)
Collections on subscriptions.................................. - 0 - (945) 945
Stock dividend on special common stock paid-in common stock .. - 0 - - 0 -
Stock dividend on preferred stock ............................ (413) (413)
Common stock subscription adjustments ........................ 162 162 - 0 -
Preferred stock cancellations ................................ 2 2
-------- ------- -------

Balance - July 31, 1994.......................................... 16,926 1,504 15,422

Transactions for the year ended July 31, 1995:
Net (loss).................................................... (505) (505)
Common stock redeemed or cancellations........................ (88) (63) (25)
Common stock to offset accounts receivable.................... (175) (175)
Collections on subscriptions.................................. - 0 - (541) 541
Stock dividend on preferred stock ............................ (291) (291)
Common stock subscription adjustments ........................ - 0 - - 0 -
-------- ------- -------

Balance - July 31, 1995.......................................... 15,867 900 14,967

Transactions for the year ended July 31, 1996:
Net (loss).................................................... (2,264) (2,264)
Common stock redeemed or cancellations........................ (19) (21) 2
Common stock to offset accounts receivable.................... (135) (135)
Collections on subscriptions.................................. - 0 - (240) 240
Stock dividend on preferred stock ............................ (191) (191)
Common stock subscription adjustments ........................ - 0 - - 0 -
-------- ------- -------

BALANCE - JULY 31, 1996.......................................... $13,258 $ 639 $12,619
======== ======= =======

Attention is directed to the foregoing accountants' report and to the
accompanying notes to financial statements.

F-5

DRUG GUILD DISTRIBUTORS, INC.

STATEMENTS OF CASH FLOWS

Year Ended July 31,
1996 1995 1994
------- -------- --------
(in thousands)

Cash flows from operating activities:
Net income (loss) ............................. $(2,264) $ (505) $ 308
Adjustments to reconcile net income (loss) to
net cash provided by (used in) operating
activities:
Depreciation and amortization .............. 891 1,031 1,321
Loss on disposal of fixed assets ........... 59
Deferred compensation payable .............. (53) (49) 88
Deferred income taxes ...................... (392) 8 (144)
(Increase) decrease in:
Trade receivables, net ................... (2,908) (6,318) (10,881)
Merchandise inventory .................... 9,456 (4,033) 5,074
Tax refund receivable .................... (1,036)
Prepaid expenses and other current
assets ................................. (14) 446 (644)
Increase (decrease) in:
Accounts payable ......................... (2,873) (4,515) 10,008
Deferred rent payable .................... 263
Accrued expenses and taxes ............... (339) 677 (167)
------- -------- --------
Net cash provided by (used in)
operating activities ............... 731 (13,258) 5,022
------- -------- --------
Cash flows from investing activities:
Additions to property and equipment ............ (880) (1,405) (568)
(Increase) decrease in other assets ............ 218 (217) (12)
------- -------- --------
Net cash (used in) investing
activities ......................... (662) (1,622) (580)
------- -------- --------
Cash flows from financing activities:
Repayment of notes payable ..................... (528) (627) (2,480)
Net increase (decrease) in short-term
bank debt .................................... (71) 15,858 (2,058)
Collections on common stock .................... 242 541 945
Common stock redeemed .......................... (24) (17)
Collections on subscriptions for preferred
stock ........................................ 77
Preferred stock redeemed ....................... (1,535) (804) (66)
------- -------- --------
Net cash provided by (used in)
financing activities ............... (1,892) 14,944 (3,599)

------- -------- --------
NET INCREASE (DECREASE) IN CASH ................... (1,823) 64 843

Cash - beginning of year .......................... 2,023 1,959 1,116
------- -------- --------
CASH - END OF YEAR ................................ $ 200 $ 2,023 $ 1,959
======= ======== ========
Supplemental disclosures of cash flow information:
Interest paid ................................ $ 5,353 $ 5,327 $ 2,915
Income taxes - paid .......................... 101 1 862
Income taxes - refunded ...................... 377 477
Summary of noncash transactions:
Reduction of accrued expenses in exchange
for issuance of notes payable ............ 19 24 22
Equipment transfer to employees .............. 56
Accounts receivable reduced for
redemptions of:
Common stock ............................. 135 177 121
Preferred stock .......................... 777
Stock dividends on preferred stock ........... 191 291 413
Stock dividends on special common stock
paid-in common stock ....................... 68
New stock subscriptions, net of cancellations:
Common stock ............................... (64) 93
Preferred stock cancellation increasing
additional paid-in capital ................. 2

Attention is directed to the foregoing accountants' report and to the
accompanying notes to financial statements.

F-6

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE A) - Summary of Significant Accounting Policies:

Description of business:

Drug Guild Distributors, Inc. (the "Company") is engaged in the business
of distributing at wholesale, a wide variety of products to drug stores and
health and beauty aid stores located primarily in the State of New Jersey, the
greater New York City metropolitan area and Connecticut.

Merchandise inventory:

The inventory, which consists entirely of finished goods, is stated at the
lower of cost (last-in, first-out) or market (see Note N).

Property and equipment:

Property and equipment are stated at cost. Depreciation is computed on
straight-line and accelerated methods over the estimated useful lives as
follows:

Leasehold improvements................ 10 - 18 years
Warehouse equipment .................. 5 years
Data processing equipment ............ 5 - 7 years
Trucks and delivery equipment ........ 5 years

Cash equivalents:

For purposes of the statement of cash flows, the Company considers all
highly liquid money market instruments with original maturity of three months or
less to be cash equivalents. At July 31, 1996, cash equivalents were deposited
in financial institutions and consisted of immediately available fund balances.

Income taxes:

The Company accounts for income taxes utilizing the asset and liability
approach requiring the recognition of deferred tax assets and liabilities for
the expected future tax consequences of temporary differences between the basis
of assets and liabilities for financial reporting purposes and tax purposes.

(continued)

F-7

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE A) - Summary of Significant Accounting Policies: (continued)

Use of estimates:

The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.

Fair value of financial instruments:

The carrying amount reported in the balance sheets for cash, accounts
receivable, accounts payable and accrued liabilities approximates fair value
because of the immediate or short-term maturity of the financial instruments.

The carrying amount reported for outstanding bank indebtedness
approximates fair value because the debt is at a variable rate that reprices
frequently. The Company believes that its nonbank indebtedness approximates fair
value based on current yields for debt instruments of similar quality and terms.

Income (loss) per common share:

For the years ended July 31, 1996, July 31, 1995 and July 31, 1994,
earnings per share was computed by dividing net income after deducting the
preferred dividend requirements, by the weighted average of common stock
outstanding of 10,062,372, 9,929,990 and 9,688,802 at July 31, 1996, July 31,
1995 and July 31, 1994, respectively.

Concentration of credit risk:

Financial instruments that potentially subject the Company to credit risk
consist of trade receivables. The Company markets its products primarily to
retail drug and health and beauty aid stores. The risk associated with this
concentration is believed by the Company to be limited due to the large number
of stores and the performance of credit evaluation procedures.

(continued)

F-8

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE A) - Summary of Significant Accounting Policies: (continued)

Recently issued accounting pronouncements:

In March 1995 and October 1995, the Financial Accounting Standards Board
issued Statement of Financial Accounting Standards No. 121 ("SFAS 121"),
"Accounting for the Impairment of Long-Lived Assets and for the Long-Lived
Assets to be Disposed of," and Statement of Financial Accounting Standards No.
123 ("SFAS 123"), "Accounting for Stock-Based Compensation," respectively. SFAS
121 is effective for the Company's fiscal year ending July 31, 1997 and SFAS 123
has various effective and transition dates. The Company believes adoption of
SFAS 121 and SFAS 123 will not have a material impact on its financial
statements.

(NOTE B) - Trade Receivables:

Trade receivables include notes due from customers, as follows:

July 31, 1996
-------------
Maturing within one year:
Stockholder ............... $2,478,000
Nonstockholder ............ 2,384,000
----------
4,862,000
----------
Due after one year:
Stockholder ............... 1,764,000
Nonstockholder ............ 2,338,000
----------
4,102,000
----------

Total .............. $8,964,000
==========

July 31, 1995
-------------

Maturing within one year ..... $4,820,000
Due after one year ........... 5,075,000

Total.... .......... $9,895,000
==========

It is the policy of the Company to obtain either personal guarantees or a
lien on the customer's assets as collateral for most notes and certain other
trade receivables. See Note L for other collateral received.

(continued)

F-9

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

NOTE C) - Loans Payable - Bank:

Under an accounts receivable and inventory financing agreement, which
allows for borrowings of up to $80 million, a bank makes secured demand loans
based on a percentage of eligible trade receivables and inventory, which are
pledged as collateral. Interest is at 1 1/4% above the prime rate. As of July
31, 1996, total loan advances available under the revolving loan agreement was
$3,935,000. The agreement contains restrictions, which limit cash dividends and
redemptions of stock.

For the year ended July 31, 1996, a waiver was obtained from the bank for
the redemptions of preferred stock during the year and for the period through
November 1996 in the amount not exceeding $413,000.

(NOTE D) - Notes and Loans Payable:

Short-term and long-term portion of notes and loans payable are as
follows:
July 31,
----------------------
1996 1995
--------- ----------
Notes and loans due to stockholders,
officers, employees and members of their
families are payable on demand and 13
months after demand. Interest is at rates
ranging from prime to 1 1/4% over prime,
except that $472,000 and $623,000 of such
notes at July 31, 1996 and July 31, 1995,
respectively, require minimum interest of
10% .......................................... $571,000 $ 756,000

Notes due in installments of principal
and interest at 9% - 11 1/2% to
November 1999 are collateralized by
specific equipment ......................... 193,000 517,000
--------- ----------

764,000 1,273,000

Due on demand or within one year .............. 527,000 772,000
--------- ----------

Long-term portion ............................. $237,000 $ 501,000
========= ==========

(continued)

F-10

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE D) - Notes and Loans Payable: (continued)

As of July 31, 1996, future annual maturities are as follows:

Year Ending
July 31,
-----------
1997 ............................... $ 541,000
1998 ............................... 195,000
1999 ............................... 38,000
2000 ............................... 13,000
---------

Total annual maturities ........ 787,000
Less amounts representing
interest ..................... (23,000)
---------
Present value at annual
maturities ................... $ 764,000
=========

(NOTE E) - Property and Equipment:

Property and equipment consists of the following:

July 31,
---------------------------
1996 1995
------------ ------------
Leasehold improvements ...... $ 2,303,000 $ 2,275,000
Warehouse equipment ......... 2,539,000 2,530,000
Data processing equipment ... 7,409,000 6,712,000
Trucks and delivery
equipment ................ 1,747,000 1,601,000
Furniture and fixtures ...... 289,000 289,000
------------ ------------
14,287,000 13,407,000
Less accumulated depreciation
and amortization ......... (10,956,000) (10,066,000)
------------ ------------
$ 3,331,000 $ 3,341,000
============ ============

(NOTE F) - Deferred Compensation:

The Company has a deferred compensation agreement with its former
president, providing for monthly payments of $8,333 through February 2004. The

Company had previously provided for the present value of these payments.

There was no deferred compensation expense for the years ended July 31,
1996 and July 31, 1995. The expense was $106,000 for the year ended July 31,
1994.

(continued)

F-11

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE G) - Retirement Plans:

The Company maintains a noncontributory defined benefit pension plan for
its eligible nonunion employees which was frozen June 28, 1996, accordingly,
service costs subsequent to the date of freezing are excluded from benefit
accruals under the plan.

The benefits under this plan are based on the participants' length of
service and compensation (subject to the Employee Retirement Income Security Act
of 1974 and to the Internal Revenue Service limitations). The funding policy for
this plan is to contribute amounts actuarially determined as necessary to
provide sufficient assets to meet the benefit requirements of the plan retirees.

The following table sets forth the Plan's funded status and amounts
recognized in the Company's balance sheets as of July 31:

1996 1995
----------- -----------
Actuarial present value of
benefit obligations:
Accumulated benefit obligation,
including vested benefits of
$1,172,000 and $2,071,000,
respectively .......................... $(1,175,000) $(2,073,000)
=========== ===========

Projected benefit obligation for
service rendered to date .................. $(1,671,000) $(2,654,000)

Plan assets at fair value, primarily
consisting of U.S. Government
guaranteed securities and bank
certificates of deposit ................... 1,518,000 2,276,000
----------- -----------

Projected benefit obligation in
excess of plan assets ..................... (153,000) (378,000)

Unrecognized net loss from past
experience different from that
assumed and effects of changes
in assumptions ............................ 448,000 526,000

Unrecognized net obligations as of
August 1, 1987, net of
amortization .............................. 16,000 18,000

Adjustment to prior service cost not
yet recognized in net periodic
pension cost .............................. (8,000) (9,000)
----------- -----------

Deferred pension cost ........................ $ 303,000 $ 157,000
=========== ===========

(continued)

F-12

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE G) - Retirement Plans: (continued)

Net pension cost included the following components:

1996 1995 1994
--------- --------- ---------
Service cost - benefits
earned during the period ....... $ 101,000 $ 106,000 $ 180,000

Interest cost on projected
benefit obligation ............. 157,000 166,000 195,000

Actual return on plan
assets ......................... (112,000) (122,000) (57,000)

Net amortization and
deferral ....................... (3,000) 17,000 (52,000)
--------- --------- ---------

Net periodic cost ................. $ 143,000 $ 167,000 $ 266,000
========= ========= =========

The weighted average discount rate and rate of increase in future
compensation levels used in determining the actuarial present value of the
projected benefit obligation were 7.0% and 4.0%, respectively, for 1996 and 6.5%

and 4.0%, respectively, for 1995 and 6.5% and 5.0%, respectively, for 1994. The
expected long-term rate of return on assets was 7.0% for 1996 and 6.5% for 1995
and 1994.

The Company makes contributions along with other employers to a union
multi-employer plan, Local 815, International Brotherhood of Teamsters. The
expense for such plan was $351,000, $349,000 and $336,000 for the years ended
July 31, 1996, July 31, 1995 and July 31, 1994, respectively. The Employee
Retirement Income Securities Act of 1974, as amended by the Multi-Employers
Pension Plan Amendment Act of 1980, imposes certain liabilities upon employers
who are contributors to multi-employer plans in the event of such employers'
withdrawal from such a plan or upon a termination of such a plan. The share of
the plan's unfunded vested liabilities allocable to the Company, if any, and for
which it may be contingently liable, is not ascertainable at this time.

The Company also has a profit-sharing plan and a 401(k) savings plan for
eligible nonunion employees. The 401(k) plan is solely funded by employee
contributions. The profit-sharing plan requires no fixed or minimum
contribution. There was no profit-sharing expense for the years ended July 31,
1996, July 31, 1995 and July 31, 1994.

(continued)

F-13

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE H) - Officer's Life Insurance:

The Company is the owner and beneficiary of insurance policies of
$1,600,000, on the life of its former president.

(NOTE I) - Commitment and Contingencies:

In March 1995, the Company renewed two lease agreements extending the
terms to expire in May 2005, for real estate in Secaucus, New Jersey. Both
leases contain termination clauses whereby the Company may terminate the lease
between between December 1, 1997 and November 30, 1998 by paying a fee equal to
six months of rent.

In addition, the Company is obligated under another lease for warehouse
space expiring March 1997.

Future minimum annual lease payments are as follows:

Year Ending
July 31,
-----------
1997.......................... $1,021,000

1998.......................... 912,000
1999.......................... 912,000
2000.......................... 946,000
2001.......................... 1,056,000
Thereafter..................... 4,048,000
----------
$8,895,000
==========

Total rent expense, including real estate taxes, were $1,291,000,
$1,016,000 and $1,001,000 for the years ended July 31, 1996, July 31, 1995 and
July 31, 1994, respectively.

Deferred rent payable represents the excess of rental expense determined
on a straight-line basis over the amounts currently payable pursuant to the
leases.

(NOTE J) - Registered Public Offering:

Pursuant to a Registration Statement on Form S-2 filed with the United
States Securities and Exchange Commission on June 10, 1991 and most recently
updated August 31, 1994, the Company is offering up to 4,500,000 shares of its
common stock, $1 par value, and up to 55,000 shares of its preferred stock, $100
par value. Of the common stock, 3,000,000 shares are offered for sale and
1,500,000 shares are reserved for the issuance of dividends. Of the preferred
stock,

(continued)

F-14

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE J) - Registered Public Offering: (continued)

37,500 shares are offered for sale and 17,500 shares are reserved for the
issuance of dividends (see Note K). Shares of common stock may be sold either
outright or pursuant to a subscription. Subscriptions are in the amount of
$18,000, payable over 60 months at $300 per month. Payments are applied toward
the purchase of shares at the FIFO Book Value (book value adjusted for inventory
and tax liabilities, stated as if the inventory was valued at the lower of
first-in, first-out cost or market) at the close of the fiscal quarter
immediately preceding the date of payment. As of July 31, 1996, the FIFO book
value was $1.55 per share.

(NOTE K) - Redeemable Preferred Stock:

Preferred stockholders are entitled to an 8% cumulative dividend based on

par value, payable in preferred stock. Upon liquidation of the Company, holders
of the preferred stock are entitled to a payment of $100 per share before any
amounts are paid to holders of common stock. The preferred stock is not entitled
to vote and does not have any preemptive or conversion rights.

Holders of preferred stock have the right to require the Company to
repurchase their shares at par value ($100.00) commencing five years after full
payment for the stock has been made.

The Company may call preferred stock at any time. The call price is 105%
of par value if shares are called within the first year of issue, 110% of par
value within the second year, 115% within the third year, 120% within the fourth
year and 125% after four years.

A holder of shares of preferred stock desiring to sell his shares to a
third party must first offer them to the Company at the repurchase price. If the
Company elects to accept such offer, it is obligated to pay for such shares in
three equal annual installments, without interest, the first such installment to
be made 60 days after such offer.

Shares are sold under a five year subscription plan. Subscribers are
required to pay a minimum of $4,500 per year towards a $22,500 subscription
unit. Shares are issued as of July 31 of each year at the rate of one share per
$100, provided that at least the minimum has been paid. Upon timely completion
of total payments for the unit, the Company is required to issue 25 additional
shares as a dividend for a total of 250 shares per unit.

(continued)

F-15

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE K) - Redeemable Preferred Stock: (continued)

The amounts due within the next five years, if fully paid units of
preferred stock held five or more years are offered for redemption, are as
follows:

Year Ending
July 31,
-----------
1997 ....................... $1,930,000
1998 ....................... 183,000
1999 ....................... 476,000
----------
$2,589,000
==========

(NOTE L) - Stockholders' Equity:

The stockholders represent a substantial portion of the Company's
customers. Each stockholder has assigned his shares to the Company as collateral
for his liability to the Company on open account. The transfer of shares is
restricted by agreement, and any stockholder who wishes to sell his shares must
first offer them to the Company at cost (as defined) or par value with respect
to shares issued as a stock dividend.

The common shares to be issued on subscriptions received are not
determinable until collected. However, at each year end such outstanding
subscribed shares are included in the accompanying financial statements based on
the purchase price at those dates. The difference between the par value and the
purchase price of subscribed common shares has been credited to additional
paid-in capital. Additional paid-in capital includes $219,000 on such
uncollected subscriptions at July 31, 1996 and $475,000 at July 31, 1995.

(NOTE M) - LIFO Inventory:

A liquidation of LIFO inventory layers, which were carried at lower costs
as compared to current costs, had the effect of increasing net income by
approximately $679,000 and $375,000 for the years ended July 31, 1996 and July
31, 1994, respectively.

Had inventories been valued using the first-in, first-out method, they
would have been greater by approximately $4,763,000 at July 31, 1996 and
$10,087,000 at July 31, 1995.

(continued)

F-16

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE N) - Income Taxes:

A provision (credit) for income taxes differs from the amounts computed by
applying the maximum Federal income tax rate to the pre-tax income, as follows:

Year Ended July 31,
------------------------------------------------------------------
1996 % 1995 % 1994 %
----------- ----- --------- ----- --------- ----

Computed tax at maximum
rate ................ $(1,294,000) (34.0) $(201,000) (34.0) $ 159,525 34.0
State taxes on income,

net of Federal income
tax benefit (expense) (231,000) (6.0) 36,000 6.1 29,090 6.2
Alternative minimum tax
credit .............. (156,000) (4.1)
Other adjustments ...... 138,000 3.6 79,000 13.4 (27,615) (5.9)
----------- ----- --------- ----- --------- ----

$(1,543,000) (40.5) $ (86,000) (14.5) $ 161,000 34.3
=========== ===== ========= ===== ========= ====

Deferred tax assets are comprised of the following:

Year Ended July 31,
-------------------------
1996 1995
----------- -----------
Current deferred tax assets (liabilities):
Allowance for doubtful accounts ........ $ 634,000
Inventory overhead ..................... 131,000
Other .................................. 23,000
Federal NOL carryforward ...............
AMT credit .............................
-----------
Total current deferred tax
asset (liabilities) ........... 788,000
-----------
Noncurrent deferred tax assets (liabilities):
Deferred compensation .................. $ 228,000 250,000
Depreciation ........................... (83,000) 82,000
Deferred pension cost .................. (121,000) (86,000)
Allowance for doubtful accounts ........ 657,000
Inventory overhead ..................... 95,000
Other ..................................
Federal NOL carryforward ............... 237,000
AMT credit ............................. 156,000
State Income tax benefit ............... 257,000
----------- -----------
Total noncurrent deferred
tax asset (liabilities) ......... 1,426,000 246,000
----------- -----------

Total deferred tax asset .......... $ 1,426,000 $ 1,034,000
=========== ===========

(continued)

F-17

DRUG GUILD DISTRIBUTORS, INC.

NOTES TO FINANCIAL STATEMENTS

(NOTE N) - Income Taxes: (continued)

As of July 31, 1996, the Company has a net operating loss carryforward for
income tax purposes aggregating approximately $697,000 which expires 2011.

(NOTE O) - Inventory Defalcation:

During 1996, an inventory defalcation was discovered. Management estimates
that 1996 results were negatively impacted by $7,400,000. The Company believes
that certain entries in its perpetual inventory and units sold were improper.
Management extrapolated the effects of these entries based on unit costs, units
sold and sales dollars. The loss is presented as a separate line item in the
statement of operations.

Management believes that similar inventory defalcations also occurred
during prior years and amounted to $5,200,000 and $2,100,000 for the years ended
July 31, 1995 and July 31, 1994, respectively. Those amounts are included in the
cost of sales for those years. The Company's reported inventory values on its
1995 and 1994 balance sheets were based on results of physical counts and,
accordingly, the Company believes that its reported net income (loss) for all
periods is fairly presented.

(NOTE P) - Subsequent Event:

On September 24, 1996, the Company's Board of Directors approved a
Definitive Agreement and Plan of Merger with Neuman Health Services, Inc. and
Neuman Distributors, Inc. distributors of pharmaceuticals and health and beauty
products. The agreement provides that the Company would be merged into Neuman
and the pre-merger shareholder of the Company would retain approximately 23% of
the merged company. The proposed merger is subject to the approval by the
Company's shareholders having beneficial ownership of a majority of the issued
and outstanding shares of each of the Company's common and preferred stock.

F-18

DRUG GUILD DISTRIBUTORS, INC.

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS

FOR THE YEARS ENDED JULY 31, 1996, JULY 31, 1995 AND JULY 31, 1994

Balance at Charged to Deductions Balance at
beginning cost and Charged to from end of
Description of period expenses other accounts reserves period

Year ended July 31, 1994:
Allowance for doubtful accounts ........ $1,134,000 $ 480,000 $419,000 (A) $ 667,000 (B) $1,366,000
========== ========== ======== ========== ==========
Year ended July 31, 1995:
Allowance for doubtful accounts ........ $1,366,000 $ 720,000 $127,000 (A) $ 630,000 (B) $1,583,000
========== ========== ======== ========== ==========
Year ended July 31, 1996:
Allowance for doubtful accounts ........ $1,583,000 $1,430,000 $288,000 (A) $1,660,000 (B) $1,641,000
========== ========== ======== ========== ==========

(A) Recovery of amounts previously written off.

(B) Balances written off.

Attention is directed to the foregoing accountants' report and to the
accompanying notes to the financial statements.

F-19